GlassScriptPhysician profile
Pamela Geppert
NPI 1073591608
$564.83
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $251 · 2021: $313.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.98 | 2020-2021 | |
| Amarin Pharma, INC. | $110.58 | 2020-2021 | |
| Lilly USA, LLC | $86.34 | 2020-2021 | |
| Amgen INC. | $60.63 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.87 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $30.45 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.65 | 2020-2021 | |
| Indivior INC. | $22.66 | 2020 | |
| Allergan, INC. | $18.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.06 | 2021 | |
| Merck Sharp & Dohme LLC | $13.42 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Geppert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.